Evidence map›Paper›PMID 31646189›Full record

ArticleCommunications biology2019

Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake.

Song Yi Ko, WonJae Lee, Hilary A Kenny, Long H Dang, Lee M Ellis, Eric Jonasch, Ernst Lengyel, Honami Naora

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 123 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Proteome of CD9Life (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Extracellular vesicles inEXO : beyond the cell · 2026
    Article
  18. Review
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Song Yi Ko1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas USA.ORCID 0000-0001-6090-9003
WonJae Lee1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas USA.
Hilary A Kenny2Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois USA.
Long H Dang3Division of Hematology and Oncology, Department of Internal Medicine, University of Florida, Gainesville, Florida USA.
Lee M Ellis1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas USA.
Eric Jonasch5Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas USA.
Ernst Lengyel2Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois USA.
Honami Naora1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas USA.ORCID 0000-0003-1758-7605
The University of Texas MD Anderson Cancer Center · USUniversity of Chicago · USUniversity of Florida Health · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Regulation of Adhesion and Proteolysis in Ovarian CancerR01CA111882 · NCI · UNIVERSITY OF CHICAGO · PI LENGYEL, ERNST · 2006 to 2016
$2.8M
Pre-metastatic Omental Niche Formation in Ovarian CancerR01CA217931 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NAORA, HONAMI · 2018 to 2022
$1.8M
Mechanism of evasion by ovarian cancers from anti-VEGF therapyR01CA207034 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NAORA, HONAMI · 2016 to 2020
$1.8M
Metabolic changes in ovarian cancer cells initiated by metastasis to adipose tissR01CA169604 · NCI · UNIVERSITY OF CHICAGO · PI LENGYEL, ERNST · 2013 to 2017
$1.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA111882NCI NIH HHS R01 CA169604NCI NIH HHS R01 CA207034NCI NIH HHS R01 CA217931
6 · The paper itself

Abstract

Cancer-derived small extracellular vesicles (sEVs) induce stromal cells to become permissive for tumor growth. However, it is unclear whether this induction solely occurs through transfer of vesicular cargo into recipient cells. Here we show that cancer-derived sEVs can stimulate endothelial cell migration and tube formation independently of uptake. These responses were mediated by the 189 amino acid isoform of vascular endothelial growth factor (VEGF) on the surface of sEVs. Unlike other common VEGF isoforms, VEGF

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalBevacizumabCell Line, TumorDisease ProgressionDrug Resistance, NeoplasmEndothelial CellsExtracellular VesiclesFemaleHeparinHumansMiceMice, NudeNeovascularization, PathologicReceptors, Vascular Endothelial Growth FactorTumor MicroenvironmentAntineoplastic Agents, ImmunologicalBevacizumabHeparinReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsVEGFA protein, humanCancer microenvironmentExtracellular signalling moleculesTumour angiogenesis

Identifiers

PMID31646189
PMCPMC6802217
OpenAlexW2980760560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.